首页|达格列净治疗T2DM合并无症状高尿酸血症的疗效和安全性研究

达格列净治疗T2DM合并无症状高尿酸血症的疗效和安全性研究

扫码查看
目的 探讨达格列净治疗2 型糖尿病(T2DM)合并高尿酸血症的疗效和安全性.方法 122 例2 型糖尿病患者合并无症状高尿酸血症患者,随机分为对照组和观察组.对照组60 例经过口服二甲双胍片1 片tid联合磷酸西格列汀片1 片QD治疗.观察组62 例经过口服二甲双胍1 片tid联合达格列净片1 片QD治疗.两组患者均经过12 周治疗.比较两组患者治疗前后的空腹血糖水平(FPG)、餐后2h血糖水平(2h PG)、糖化血红蛋白(HbAlc)、血尿酸(BUA)、血肌酐(Scr)、尿素氮(BUN)和不良反应发生情况.结果 对照组1 例失访.观察组 2 例未完成随访,其中1 例因发生泌尿系感染,1 例因胃肠道不耐受退出试验.治疗12 周后观察组FPG、2 h PG、HbAlc、BUA和BUN均有显著性下降,而治疗后血糖达标率,Scr和不良反应两组无统计学差异.结论 口服达格列净片治疗2 型糖尿病合并无症状高尿酸血症能有效控制血糖,降低血尿酸水平,延缓相关并发症,具有一定的临床推广应用价值.
Efficacy and Safety of Oral Dapagliflozin in the Treatment of Type 2 Dia-betes Mellitus Complicated with Asymptomatic Hyperuricemia
OBJECTIVE To investigate the efficacy and safety of dapagliflozin in the treatment of type 2 diabe-tes with hyperuricemia.METHODS 122 patients with type 2 diabetes complicated with asymptomatic hyperurice-mia were randomly divided into control group(n =60)and observation group(n =62).62 patients in the observa-tion group were treated with oral metformin 1 tablet tid combined with Dapagliflozin 1 tablet qd.Patients in both groups were treated for 12 weeks.The fasting blood glucose level,2 h blood glucose level,HbA1c,serum uric acid(BUA),serum creatinine(Scr),blood urea nitrogen(BUN)and adverse reactions were compared between the two groups before and after treatment.RESULTS The fasting blood glucose level,2 h blood glucose level,HbAlc,BUA and BUN in the observation group were significantly decreased,but there was no significant difference in Scr and ad-verse reactions between the two groups.CONCLUSION Oral administration of Dapagliflozin tablets in the treat-ment of type 2 diabetes with asymptomatic hyperuricemia can effectively control blood glucose,reduce the level of BUA and delay related complications,which has certain value of clinical application.

DapagliflozinSitagliptinMetforminDiabetesHyperuricemia

赵艳花、王青云、朱伟、金玉婷

展开 >

义乌市中心医院,浙江义乌 322000

达格列净 西格列汀 二甲双胍 糖尿病 高尿酸血症

2020年浙江省医学会临床科研基金项目

2020ZYC-A128

2024

海峡药学
中国药学会福建分会

海峡药学

影响因子:0.643
ISSN:1006-3765
年,卷(期):2024.36(3)
  • 9